$800 Thousand is the total value of Bain Capital Life Sciences Investors, LLC's 34 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 33.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SWTX | Sell | SPRINGWORKS THERAPEUTICS INC | $79,313 | -36.9% | 3,081,307 | -36.2% | 9.91% | -29.4% |
| NTRA | Sell | NATERA INC | $38,875 | -30.9% | 700,197 | -50.0% | 4.86% | -22.7% |
| CARA | Sell | CARA THERAPEUTICS INC | $10,824 | -62.6% | 2,204,449 | -18.2% | 1.35% | -58.2% |
| Sell | THIRD HARMONIC BIO INC | $2,639 | -46.7% | 640,631 | -44.4% | 0.33% | -40.3% | |
| ACAD | Exit | ACADIA PHARMACEUTICALS INC | $0 | – | -701,402 | -100.0% | -1.25% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -2,364,410 | -100.0% | -2.88% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Bain Capital Life Sciences Partners, LP #1
- Bain Capital Life Sciences Fund, L.P. #2
- BC SW, LP #3
- Bain Capital Life Sciences Investors II, LLC #4
- Bain Capital Life Sciences Fund II, L.P. #5
- BCLS II Investco (GP), LLC #6
- BCLS II Investco, LP #7
- Bain Capital Life Sciences III General Partner, LLC #8
- Bain Capital Life Sciences Fund III, L.P. #9
- Bain Capital Life Sciences Opportunities III GP, LLC #10
- Bain Capital Life Sciences Opportunities III, LP #11
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| APTINYX INC | 20 | Q1 2023 | 16.9% |
| SOLID BIOSCIENCES INC | 19 | Q3 2022 | 22.2% |
| SPRINGWORKS THERAPEUTICS INC | 17 | Q3 2023 | 41.8% |
| DICERNA PHARMACEUTICALS INC | 16 | Q3 2021 | 58.6% |
| DYNAVAX TECHNOLOGIES CORP. | 16 | Q3 2023 | 12.4% |
| SAVARA INC | 16 | Q3 2023 | 6.0% |
| X4 PHARMACEUTICALS INC | 16 | Q3 2023 | 3.2% |
| ARCUTIS BIOTHERAPEUTICS, INC. | 15 | Q3 2023 | 20.1% |
| MERSANA THERAPEUTICS, INC. | 14 | Q3 2023 | 8.4% |
| CRINETICS PHARMACEUTICALS, INC. | 14 | Q3 2023 | 5.4% |
View Bain Capital Life Sciences Investors, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-14 |
| 13F-HR | 2024-02-13 |
| 3 | 2024-02-07 |
| 4 | 2024-01-12 |
| 3 | 2023-12-29 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 3 | 2023-05-30 |
| 4 | 2023-05-30 |
| 13F-HR | 2023-05-15 |
View Bain Capital Life Sciences Investors, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.